🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm 🔗 ow.ly/VtAE50VP4Jf

Ready for #ESMOBreast25? Big news, fresh science, and a global conversation on #BreastCancer are coming! Follow the #ESMOAmbassadors and stay up to date! #BCSM ESMO - Eur. Oncology

🤖Large prospective trials are now exploring how AI tools should be integrated in cancer screening programmes. 👉Read the view of Suzette Delaloge in the #ESMODailyReporter on uncertainties & opportunities 🔗 ow.ly/q0SW50VR6eW #AIOncology #HealthAI #HealthData #ESMOAI25

What were the long-term outcomes for patients with HER2+ early breast cancer and rare special histologies in the ALTTO trial? Pass by Riccardo Gerosa MD and his poster at #ESMOBreast25 Guilherme Nader Marta Diogo Martins Branco Evandro de Azambuja, MD, PhD Breast International Group

Do clinicians and patients see the same picture? In adjuvant BC therapy trials, agreement on side effects is weak. Patient-reported outcomes (#PROs) show symptoms that doctors often don't see. Both views are vital for patient-centred care. #ESMOBreast25

📣 Updated ESMO #ClinicalPracticeGuideline on #localised #rectalcancer: tailored intensification/de-intensification, complex radiological factors, #biomarkers & organ-preserving Tx options. #ESMOGuidelines 🔗 ow.ly/q2VV50VWTAU

Very happy to be able to share with you that the ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) is now available: authors.elsevier.com/c/1l8Rk3I2OQmT…

ESMO-MCBS v2.0 is now out. Significant enhancements in cancer therapies evaluation: > robust 🔍 understanding of score’s meaning, ➕ accuracy, fairness, utility of treatment assessments, 🪞 advances in science, clinical practice, patient input.

🤖 Discover the new ESMO AI & Digital Oncology Hub, a virtual place for medical oncologists seeking content, expert perspectives, practical resources & guidance on AI and digital technologies in oncology 🔗 ow.ly/y5t150W05jj #AIOncology #HealthAI #ESMOAI25

Join us at #ASCO25 tomorrow to discuss the efficacy of immune checkpoint inhibitors in patients with CNS metastases from solid tumors, a group often overlooked in clinical trials Soraia Lobo-Martins Diogo Martins Branco Evandro de Azambuja, MD, PhD Marco Tagliamento Elisa Agostinetto Eva Blondeaux Matteo Lambertini, MD PhD

👉 ESMO Living Guidelines on Renal Cell Carcinoma v1.1: New title with updated recommendations and algorithms from the published Guideline in an interactive format. 🔗 ow.ly/X3AU50W8PEi

ESMO announces the 2025 election results for the Director positions & the Nomination Committee. Thank you to all #ESMOMembers who voted & contributed to shaping the Society’s future direction 📢Curious to see who was elected? 🔗Read the full announcement ow.ly/fJgs50W92CJ

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines

👉 Access the core content of the Metastatic Breast Cancer Living Guideline in a user-friendly format ready for you to use in your own presentations. 🔗 ow.ly/Ax0y50WcSQR

📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance. #LungCancer #mNSCLC #ESMOGuidelines 🔗 ow.ly/v7nE50Wbqsf

Diversity in clinical trials: Maghreb pts have younger age and more aggressive BC but similar survival outcomes doi.org/10.1016/j.clbc… Chiara Dauccia Véronique Debien Soraia Lobo-Martins Elisa Agostinetto Luca Arecco, MD Diogo Martins Branco

Post #ESMOGI25 reflection 💭 4 phase III trials reported #QualityofLife data 👉MATTERHORN 👉PANOVA3 👉CheckMate9DW 👉CheckMate8HH ‼️QoL important for regulators (+doctors/patients🫂) ✅ESMO - Eur. Oncology #MCBS QoL scoring BUT 📝Do we capture QoL well? ⌚️Could #DigitalOncology help?👇

👉 ESMO Living Guidelines on Localised Rectal Cancer: New title in the library with all recommendations and algorithms from the published Guideline in an interactive format. #ESMOGuidelines 🔗 ow.ly/PggR50WkRKH erika martinelli

🤖 #ESMOAI25: Help us advance cancer care through technology 🚨 Your insights will help drive the evolution of AI and digital solutions in oncology. ⏰ Submit your research by 2 September 2025. #HealthAI 🔗 ow.ly/pjIQ50Wia3a